fda warning letters compounded semaglutide tirzepatide september 2025 Why the Issued 30 to Telehealth Sites Marketing GLP-1s FDA Drug Recalls and Warnings:

Simply note your current or most recent dose on your intake form your clinician will review it and confirm the right starting point for your treatment

Moreover, because the analysis was restricted to patients who completed 36 weeks of treatment, the findings may not be generalizable to individuals who discontinued therapy earlier

[8] Is weight loss inevitable

Exomind, our advanced brain stimulation therapy, is designed to promote emotional balance, reduce stress, and enhance mental clarityall of which can support successful weight management

So protein, healthy fats and fiber are all going to help to stimulate GLP-1 production and release, but it's also going to promote feelings of fullness and help regulate your blood sugar

On January 5, 2026, Novo Nordisk introduced oral Wegovy (semaglutide), marking the first FDA-approved oral GLP-1 therapy for chronic weight management, offering a daily pill alternative to weekly injections